Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gossamer Bio
Biotech
Gossamer and Chiesi pull the plug on PAH drug collaboration
After signing a $486 million biobuck deal with Italian biopharma Chiesi in 2024, Gossamer Bio has ended the collaboration and licensing agreement.
Will Maddox
Jul 27, 2026 10:03am
Gossamer Bio fails phase 3 pulmonary arterial hypertension trial
Feb 23, 2026 9:50am
Chiesi buys into Gossamer's Winrevair rival
May 6, 2024 10:28am
Former FDA leader Woodcock inspires Biotech Sisterhood summit
Apr 24, 2024 9:23am
BIO announces new CEO—Chutes & Ladders
Dec 8, 2023 9:30am
Gossamer cuts loose staff, ties future to tarnished Merck rival
May 10, 2023 6:30am
